Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A
Individuals with clinically severe haemophilia A, including subgroups previously excluded from clinical trials, successfully transitioned to efanesoctocog alfa with excellent hemostatic outcomes and no inhibitor recurrence.
Authors
- Natalie Johnston
- Stacy E. Croteau (ORCID: https://orcid.org/0000-0001-6112-6166)
- Debbie Jiang (ORCID: https://orcid.org/0000-0002-2978-3585)
- Daniel Echelman
Institutions
- Boston Children's Hospital (US)
- Massachusetts General Hospital (US)
- Boston Children's Museum (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1111/hae.70175
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00